Blog Single

Executive Summary. Electronic health record and health IT software companies are typically valued on a mix of recurring revenue quality, customer retention, implementation stickiness, and the difficulty patients and providers face when switching systems. For San Francisco business owners in this sector, the headline ARR figure matters, but it does not tell the full story. Buyers and investors also test net revenue retention, churn, implementation complexity, regulatory exposure, and the strength of the switching cost moat. These factors can justify premium valuation multiples, particularly when growth is durable, customer concentration is manageable, and the software is embedded in the daily workflows of providers, payers, or life sciences customers.

Introduction

Electronic health record (EHR) and broader health IT businesses occupy a unique corner of the software market. Their valuation is shaped not only by growth and profitability, but also by how deeply the product is integrated into clinical operations, billing, compliance, and reporting. A system that stores patient data, supports workflow, and becomes the operational backbone of a practice or hospital is far harder to replace than a generic business application.

That is why valuation professionals do not rely on EBITDA alone when assessing an EHR software company. In most cases, the most relevant methods are revenue multiples, ARR-based analysis, discounted cash flow modeling, and precedent transactions. The right multiple depends on how visible the revenue is, how sticky the platform has become, and whether the company can sustain expansion without expensive customer acquisition. For founders in SoMa, Mission Bay, or the broader Bay Area health technology ecosystem, understanding these drivers is essential before raising capital, negotiating a sale, or planning a liquidity event.

Why This Metric Matters to Investors and Buyers

Recurring revenue is the foundation of software valuation, but not all recurring revenue is equal. In EHR and health IT, buyers care about contracted ARR because it suggests predictability and reduces forecast risk. However, they also look closely at how that ARR behaves over time. A company with $15 million of ARR and 115 percent net revenue retention may be more valuable than a larger company with $25 million of ARR and 90 percent retention, because the former can grow efficiently from the existing customer base.

NRR measures how much revenue is retained and expanded from existing customers after churn, downgrades, and upsells. In software valuation, strong NRR is often a signal of product-market fit and pricing power. For EHR software, an NRR above 110 percent is typically viewed favorably, while 120 percent or more can support premium multiples if the company also has low gross churn and a disciplined go-to-market engine. In contrast, if churning clients are common or if revenue depends on one-time implementation fees, a buyer may discount the multiple because the business lacks true retraining and renewal visibility.

Implementation stickiness also matters because health IT products are not easily swapped out. Once a system is linked to scheduling, charting, coding, revenue cycle management, compliance workflows, and integrations with labs or imaging providers, the replacement cost rises sharply. That operational entrenchment creates a switching cost moat. Buyers are often willing to pay more for that moat because it lowers the risk of revenue disruption and creates long-duration customer relationships.

Key Valuation Methodology and Calculations

ARR Multiples and Software Comparables

For many EHR and health IT businesses, ARR multiples are the most intuitive starting point. The relevant multiple depends on growth, retention, margin profile, market size, and product category. Early-stage or subscale software businesses with strong growth but limited profitability may trade on forward ARR multiples rather than EBITDA multiples. More mature companies, especially those with slower growth or heavier services components, are often evaluated on a blended basis that includes revenue, EBITDA, and cash flow.

As a general framework, a health IT company with annual recurring revenue growth above 30 percent, NRR above 115 percent, and gross margins above 75 percent may command a materially higher multiple than one growing at 10 percent with flat retention. The market rewards durable expansion. In contrast, if implementation services account for a large portion of revenue, margins may be lower and a revenue multiple may weaken accordingly. Buyers discount revenue that is less recurring or that requires significant human labor to deliver.

Public market comparables and precedent transactions both matter, but the final valuation must reflect private-company reality. A venture-backed software company in the Bay Area may cite public SaaS multiples, yet buyers will still apply a discount for customer concentration, product maturity, and execution risk. In practice, recurring revenue businesses with strong retention often receive higher valuation ranges than analogous transaction-heavy software providers.

Net Revenue Retention and Churn Analysis

NRR is especially relevant in EHR valuation because users rarely leave based on price alone. They leave when product functionality, service quality, integration depth, or compliance support breaks down. If a company has NRR of 120 percent, a buyer can infer that the installed base is expanding despite normal attrition. That creates a compounding effect on value because existing customers become a growth engine rather than a static asset.

Churn must be analyzed carefully. Logo churn and revenue churn are not the same. A company may lose smaller customers while retaining larger accounts, or it may preserve logos while contracting usage. Either pattern affects value differently. If annual revenue churn is consistently above 8 percent or 10 percent, valuation pressure is likely, even if top-line growth appears strong. Buyers price risk, and elevated churn suggests that growth may require constant replacement sales rather than efficient expansion.

Another critical metric is cohort behavior. When customer cohorts retain and expand over several years, the company may deserve a premium because its economic engine is compounding. This matters in DCF modeling as well. Higher retention reduces the discount applied to future cash flows and increases terminal value, which can be more important than near-term EBITDA in software businesses.

Implementation Stickiness and Switching Cost Moats

The implementation process in EHR and health IT is often long, expensive, and disruptive. Data migration, staff training, workflow redesign, APIs, regulatory configuration, and historical record preservation all create friction. A system that has already been embedded into billing and care delivery is not just software, it is part of the operating model. That is the essence of implementation stickiness.

Valuation professionals look for evidence that stickiness is real, not assumed. Strong indicators include multi-year contracts, high renewal rates, usage expansion after go-live, and deep integrations with third-party systems. If a product is mission-critical and the cost of switching is measured in time, training, regulatory risk, and lost productivity, then the business may deserve a premium over a generic SaaS company with similar revenue.

This is particularly relevant in California, where health systems, physician groups, and digital health companies face dense compliance obligations, wage pressures, and competitive labor markets. In the Bay Area, where enterprise software sophistication is high, buyers understand that a sticky product can protect margins. But they also underwrite implementation risk carefully, especially if onboarding requires significant services staffing or if the customer success model has not scaled efficiently.

DCF, EBITDA Multiples, and the Right Lens

Discounted cash flow analysis remains essential when a business has predictable retention and a clear path to profitability. In an EHR company, DCF can capture the long tail of recurring renewals and upsells that a simple EBITDA snapshot might miss. A well-built DCF should reflect realistic churn, ramp timelines for new customers, implementation cost timing, and operating leverage as the installed base grows.

EBITDA multiples still matter, especially for mature software companies or transactions involving strategic buyers. However, EBITDA can understate the economic value of a company that is investing heavily in growth. If implementation and sales expenses are temporarily elevated, the business may still be highly valuable because those investments build the recurring base. Buyers often adjust for this by using a forward-looking multiple, or by valuing the company on ARR and then cross-checking the implied EBITDA economics.

In a practical valuation engagement, the best answer usually comes from triangulation. If ARR multiples suggest a value of $40 million, DCF implies $42 million, and precedent transactions support a range of $38 million to $45 million, the final conclusion may fall within that band after adjustments for concentration, technical debt, and customer mix.

San Francisco Market Context

San Francisco business owners in health IT operate in a market that is highly influenced by venture capital, enterprise SaaS buying behavior, and broader Bay Area deal activity. Investors in San Francisco and nearby Silicon Valley often expect software businesses to show strong rule-of-40 style performance, where growth and margin together indicate scalable economics. That mindset can lift multiples for EHR platforms with strong retention and credible expansion paths into adjacent workflows such as revenue cycle management, analytics, patient engagement, or interoperability.

At the same time, California-specific considerations can affect seller outcomes. State and local tax exposure, California capital gains planning, and entity structure all matter when a transaction is under discussion. For asset-heavy healthcare businesses, Property 13 can influence real estate-related assumptions, though most software companies are valued primarily on intangible assets and recurring cash flow. If the company has stock option grants or complex equity compensation, the tax and equity mechanics should be reviewed early, especially before entering a sale process or recapitalization.

In neighborhoods like Mission Bay and the Financial District, strategic acquirers and growth investors are particularly attentive to software platforms that solve painful healthcare workflows. The market rewards companies that combine clinical utility, compliance strength, and sticky recurring billing. In that environment, the switching cost moat is not just a theoretical concept. It is a measurable driver of value.

Common Mistakes or Misconceptions

One common mistake is valuing an EHR company solely on current EBITDA. That can understate value when the business is still in a high-investment phase but has excellent retention and expanding customer cohorts. Another mistake is treating all recurring revenue as equally durable. Subscription revenue tied to weak implementation support or poor renewal performance does not deserve the same multiple as revenue embedded in core clinical workflows.

A second misconception is assuming that high implementation fees increase value. In some cases they do, but only if they are attached to long-lived customer relationships. If implementation revenue is one-time and the core platform is easy to replace, the multiple may compress because revenue quality is weaker. Likewise, a company may report healthy top-line growth while hiding customer dissatisfaction through aggressive discounting or elevated services expense. Sophisticated buyers will look through that presentation.

Finally, owners sometimes overlook concentration risk. If a handful of hospital systems or large groups account for most revenue, the company may appear larger than it really is from a valuation perspective. Diversification, strong renewal history, and clean contract terms are often critical to preserving premium pricing.

Conclusion

EHR and health IT companies are valued on more than revenue growth alone. ARR provides the starting point, NRR reveals whether the installed base is compounding, implementation stickiness shows how embedded the platform has become, and switching costs explain why customers stay. When those factors are strong, premium multiples become easier to defend under DCF, ARR-based analysis, and precedent transaction review.

For San Francisco business owners considering a sale, capital raise, partner buyout, or estate planning transaction, the right valuation should reflect the true quality of recurring revenue and the strength of the moat. San Francisco Business Valuations helps owners assess these drivers with rigor and discretion. If you would like a confidential valuation consultation tailored to your health IT or EHR software company, contact San Francisco Business Valuations.